Nestorone + Estradiol Vaginal Ring
Segesterone Acetate + Estradiol Vaginal Ring
- User: Female
- Hormonal: Hormonal
-
Delivery type:
- Vaginal Ring
-
Intended Duration:
- Short-Acting
- Development Stage: Phase II
- Developer(s)/researcher(s): NICHD, Population Council
Details
- API: Nestorone, Estradiol
- Target: Progesterone Receptor
-
Mechanism of Action:
- Ovulation Inhibition
- Cervical Mucus Changes
- Endometrial Changes
- Inactive Materials: Silicone Elastomer
- Regimen: 1 Insertion/90 Days
- MPT: Not Potential MPT
- Promising Attributes: E2 is not associated with an increased risk of VTE and can be protective against bone mineral loss. Nestrone is a highly effective progestin. Vaginal rings align with growing user desire for user-controlled, reversable, non-invasive methods.
Product Status
Active Clinical Research
History
2018: Results from first dose-finding study of a 90 day vaginal ring containing NES and E2 published, showing sustained release of NES at contraceptive levels but E2 release below the necessary threshold to prevent bone mineral loss
2020: Results from second dose-finding study show sustained release of both NES and E2 at appropriate levels